In the latest round up of Houston innovation news you may have missed, local venture groups announce new investments, Houston schools launch programs, and more. Photo via UH.edu

It's been a horrific week for both the city of Houston and the state of Texas. Millions of residents have lost power and/or water due to a winter storm that brought low temps. For this reason, Houston innovation news may have fallen through some of the cracks.

In this roundup of short stories within Houston innovation, the Texas Medical Center's Venture Fund and Chevron Technology Ventures make new investments, University of Houston professors make big moves, both Rice University and UH announce new programs, and more.

TMCx company raises $2 million

The Texas Medical Center Venture Fund announced its latest investment. Noninvasix Inc., a startup working on novel precision oximetry technology announced it has closed an over-subscribed seed round at $2 million led by the TMC Venture Fund with support from Philips and GPG Ventures. The funds will help the company advance product development and attain FDA clearance.

"TMC Venture Fund has been a strong supporter of Noninvasix since our initial investment in the company, and we look forward to our continued partnership with them," says Tom Luby, director of TMC Innovation, in a news release. "The potential of this platform technology to guide better clinical decision-making and improve outcomes has us excited to be part of the effort that brings the optoacoustic technology to the market."

The Noninvasix team has created a solution for the safe, accurate and non-invasive monitoring of infant welfare in the neonatal intensive care unit.

"Brain hypoxia, characterized by restricted blood flow to the brain, accounts for 23 percent of all neonatal deaths worldwide and costs the U.S. healthcare system over $7 billion per year, making the development of an accurate and precise patient monitoring system a top maternal-fetal health priority," says Noninvasix CEO Graham Randall, in the release.

"Noninvasix's novel solution utilizes optoacoustic monitoring of cerebral venous oxygenation to accurately measure the adequacy of the oxygen supply to a baby's brain in real time."

The Cannon and the University of Houston launch new partnership

A UH program has teamed up with a local startup development organization. Photo courtesy of The Cannon

The Cannon has partnered up with the Wolff Center for Entrepreneurship at the University of Houston to launch a semester-long program that will introduce students to the Startup Development Organization Network.Through the new collaboration, students will have access to new opportunities to interact and connect with professionals and advisers.

"We couldn't be prouder to partner with the University of Houston and the Wolff Center for Entrepreneurship to engage with the students that will soon be driving innovation in Houston and beyond," says Jon Lambert, CEO of The Cannon, in a news release. "UH is widely recognized for its excellence in entrepreneurial education and what Dave Cook and his team have built through The Wolff Center is second to none.

"The Cannon is excited for the opportunity to play a role in enhancing the entrepreneurial education journey through helping to provide a bridge between world-class academic programming and the commercial entrepreneurial landscape."

Students at WCE will receive access to The Cannon's online platform, Cannon Connect, as well as access to exclusive events hosted by The Cannon.

Rice University launches new data science program

Rice University is now offering a master's in data science beginning in the fall. Photo courtesy of Rice

Rice University has announced it's creating a Master of Data Science program. The degree is offered through the George R. Brown School of Engineering and managed by the Department of Computer Science. With classes beginning in the fall, applications are now open.

"The field of data science touches almost every industry in our economy," says Scott Rixner, a professor in the Rice's Department of Computer Science, in a press release. "This degree will provide those seeking to find new careers, or to advance in their current careers, the opportunity to acquire an indispensable skill set and to build future-focused critical expertise that will drive future innovation."

The 31-credit program will be offer classes both online and face-to-face, according to the release. The courses will deliver the skills needed to collect, evaluate, interpret and present data for effective decision-making across a variety of industries. The new program joins the online Master of Computer Science degree that was launched in 2019.

"Data science has revolutionized all fields of study and many sectors of the industry where data is central to the scientific or industrial endeavor," says Rice Dean of Engineering Luay Nakhleh, in the release. "Data-driven discovery has complemented hypothesis-driven discovery, and it is here to stay. This degree positions our students for rewarding, life-long careers that provide meaningful impact in design and research in a multitude of industries."

Houston biotech company with COVID-19 treatment enters agreement with UH

A UH-founded biotech company has a new partnership to announce. Image via Getty Images

AuraVax Therapeutics Inc. has entered into an exclusive license agreement with the University of Houston for its intranasal vaccine and therapeutics technology platform. The biotech company is developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases including COVID-19. This new agreement upgrades the optioned intellectual property between UH and AuraVax announced in October.

The vaccine is a nasal inhalant, similar to FluMist, and was developed by Navin Varadarajan, an M.D. Anderson professor of chemical and biomolecular engineering at UH. Varadarajan is a co-founder of AuraVax.

"We are excited to rapidly expand our relationship with the University of Houston to advance the development of this novel intranasal approach to tackle respiratory viruses. We plan to stop COVID-19 at its point of entry — the nasal cavity — and we believe our intranasal platform represents a differentiated solution that will lead to a vaccine to create sustained immunity to COVID-19 and other viruses," says Varadarajan, in the news release.

Chevron Technology Ventures makes latest investment

CTV has recently invested in a geothermal energy company. Photo via eavor.com

Houston-based Chevron Technology Ventures has announced its latest investment in Eavor Technologies Inc., a Canadian company that closed a $40 million funding round. Eavor is working on a scalable geothermal technology and hopes to power the equivalent of 10 million homes by 2030.

Eavor-Loop™, Eavor's technology, uses the natural heat of the earth like a battery and is different from what's on the market because of its scalable and transportatable application — as well as because it produces zero emissions.

Along with CTV, investors included bp Ventures, Temasek, BDC Capital, Eversource1, and Vickers Venture Partners.

"I am delighted that with the funding closed in this round we can look forward to bringing down the cost of clean, dispatchable power to a universally competitive level – an important milestone for renewable energy," says John Redfern, president and CEO of the company, in a news release. "The involvement of companies such as bp and Chevron represents a fantastic endorsement of our technology, the progress we have made to date and the promise for its global scalability."

3 UH engineers named to Academy of Inventors

Three UH engineers have been named senior members of the National Academy of Inventors. Photos via UH.edu

The National Academy of Inventors have named three University of Houston Cullen College of Engineering researchers senior members for 2021.

Hien Nguyen, assistant professor of electrical and computer engineering; Jeffrey Rimer, Abraham E. Dukler Endowed Chair, William A. Brookshire Department of Chemical and Biomolecular Engineering; and Gangbing Song, Moores Professor of Mechanical Engineering, are among the 61 selected for the distinguishment, according to a press release from UH.

"This national distinction honoring the research and scholarship of Drs. Nguyen, Rimer and Song is emblematic of the reputation for innovation fostered at the Cullen College of Engineering," says Paula Myrick Short, senior vice president for academic affairs and provost at UH, in the release. "I congratulate these three outstanding faculty members for this well-deserved recognition."

Nguyen works with biomedical data analysis and artificial intelligence, Rimer's expertise in the processes behind crystal growth and formation, and Song researches the development of actuator systems for aerospace, biomedical and oil exploration applications.

A full list of NAI Senior Members is available on the NAI website.

Aziz Gilani to be recognized nationally

A Houston investor is being recognized nationally. Photo va mercuryfund.com

Aziz Gilani, managing director at Houston-based Mercury Fund, was just selected for an award from the National Venture Capital Association. Gilani is being recognized with the Outstanding Service Award for his work last year outlining and explaining the Paycheck Protection Program from the Small Business Administration to entrepreneurs.

The award will be presented at NVCA's virtual ceremony on March 9. More info on the award ceremony here.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”